Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2021 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences in November

DUBLIN, Ireland, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief...
November 08, 2021 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results

FDA review of NDA for FT218 ongoing; commercial and launch preparations progressing Presentation of new data from pivotal REST-ON clinical trial at CHEST 2021 demonstrating that treatment...
November 01, 2021 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 8th

DUBLIN, Ireland, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that it will host a...
October 19, 2021 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Presents New Data Supporting Clinical Benefit with Once-at-Bedtime FT218 and Preference for Once-Nightly Dosing in Patients with Narcolepsy at CHEST 2021

- Post-hoc responder analyses demonstrated a significantly greater proportion of patients receiving FT218 experienced reductions in weekly cataplexy attacks and improvement in mean sleep latency...
October 15, 2021 17:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Announces Ongoing FDA Review of NDA for FT218 for Patients with Narcolepsy

DUBLIN, Ireland, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that the U.S. Food and...
September 20, 2021 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Recognizes World Narcolepsy Day and Announces New Data Presentations from Pivotal Phase 3 REST-ON Trial of FT218 at Upcoming Conference

DUBLIN, Ireland, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced its support of the...
September 02, 2021 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
August 16, 2021 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Announces Publication of Data from Pivotal Phase 3 REST-ON Trial of FT218 in Adults with Narcolepsy in SLEEP

DUBLIN, Ireland, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate...
August 09, 2021 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Commercial and launch preparations on track to support potential U.S. FDA approval of FT218 for the treatment of excessive daytime sleepiness and cataplexy in adults suffering from...
August 02, 2021 08:00 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2021 Financial Results on August 9th

DUBLIN, Ireland, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company primarily focused on developing FT218, an investigational, once-nightly formulation of sodium...